Jane Street’s MoonLake Immunotherapeutics MLTX Stock Holding History

Jane Street’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.72M	Buy	92,500 +53,500	+137%	+$886K	﹤0.01%	5376
2025 Q4	$514K	Sell	39,000 -773,700	-95%	-$9.13M	﹤0.01%	7624
2025 Q3	$5.83M	Buy	812,700 +737,600	+982%	+$38.4M	﹤0.01%	3198
2025 Q2	$3.54M	Sell	75,100 -15,700	-17%	-$640K	﹤0.01%	3492
2025 Q1	$3.55M	Buy	90,800 +78,700	+650%	+$3.39M	﹤0.01%	3455
2024 Q4	$655K	Buy	+12,100	New	+$618K	﹤0.01%	6188
2024 Q3	–	Sell	-14,700	Closed	-$646K	–	10098
2024 Q2	$646K	Sell	14,700 -2,300	-14%	-$97.4K	﹤0.01%	6599
2024 Q1	$854K	Buy	17,000 +11,000	+183%	+$597K	﹤0.01%	5698
2023 Q4	$362K	Sell	6,000 -8,500	-59%	-$438K	﹤0.01%	7328
2023 Q3	$827K	Buy	+14,500	New	+$800K	﹤0.01%	5482

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street's MLTX Position: Q1 2026 in Review

Jane Street reduced its MoonLake Immunotherapeutics (MLTX) stake by 73% in Q1 2026, selling an estimated $20.3M and leaving 453,625 shares worth $8.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2751.

Jane Street first reported a position in MLTX in Q1 2022 and has held it in 12 quarters since. The position peaked at $22.2M in Q4 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Jane Street held 453,625 shares of MoonLake Immunotherapeutics worth $8.46M as of Q1 2026.
Jane Street sold 1,228,523 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $20.3M.
MoonLake Immunotherapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #2751 holding.
Jane Street first reported a position in MoonLake Immunotherapeutics in Q1 2022 and has held it in 12 quarters since.
Jane Street's MoonLake Immunotherapeutics position peaked at $22.2M in Q4 2025.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.